{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:08:52Z","timestamp":1788480532008,"version":"build-2803163510"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":2003,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Left ventricular (LV) thrombus is increasingly detected in patients with and without ischaemic heart disease due to the increased availability of cardiac magnetic resonance imaging. Risk factors include anterior ST elevation myocardial infarction, delayed reperfusion therapy, and non-ischaemic cardiomyopathy with severe LV systolic dysfunction. We aimed to report the characteristics and outcomes of patients with LV thrombus treated with either vitamin K antagonist (VKA) or direct oral anticoagulants (DOAC) with a view to describing differences in efficacy, specifically, subsequent thromboembolic events, thrombus resolution, and also side effects of therapy including clinically significant bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a retrospective, observational cohort study of patients diagnosed with LV thrombus between 1 December 2012 and 30 June 2018 and treated with either DOAC or VKA. We recorded patient demographics, past medical history, prescribed medications, and baseline investigations. The primary outcomes were rates of thromboembolism and clinically significant bleeding, with secondary outcomes of thrombus resolution on repeat cardiac imaging, repeat hospitalization, and all-cause mortality. During the study period, 84 patients were diagnosed with and managed for LV thrombus. Of these, 62 received VKA and 22 DOAC including 13 prescribed rivaroxaban, eight apixaban, and one dabigatran. Most patients 75 (89%) were male with an average age of 62 \u00b1 14 years. Ischaemic heart disease was the cause of LV impairment in 73 (87%) patients. Baseline characteristics were similar between groups at baseline. Most n = 55 (65%) were co-prescribed a single antiplatelet agent and 32 (38%) received dual-antiplatelet therapy. During an average follow-up of 3.0 \u00b1 1.4 years, there were no statistically significant differences between VKA and DOAC in rates of stroke (2% vs. 0%, P = 0.55), other thromboemboli (2% vs. 0%, P = 0.55), or clinically significant bleeding (10% vs. 0%, P = 0.13). The average interval to cardiac imaging follow-up was 233 \u00b1 251 days and was not different between groups (P = 0.83), and there was no difference in the rate of resolution of thrombus (76% vs. 65% P = 0.33). Rehospitalization (50% vs. 45%: P = 0.53) and all-cause mortality (10% vs. 14%; P = 0.61) were also similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggest that DOACs are likely to be at least as effective and safe as VKA for stroke prevention in patients with LV thrombus and, despite their lack of a licence for this indication, are therefore likely to represent a reasonable and more convenient option for this setting. The optimal timing and type of anticoagulation for LV thrombus, as well as the role of screening for high-risk patients, should be tested in prospective, randomized trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12718","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T06:13:05Z","timestamp":1593065585000},"page":"2032-2041","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Direct Oral Anticoagulants Compared to Vitamin K Antagonist for the Management of Left Ventricular Thrombus"],"prefix":"10.1093","volume":"7","author":[{"given":"Hansa","family":"Iqbal","sequence":"first","affiliation":[{"name":"School of Medicine, University of Leeds , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Straw","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Craven","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Stirling","sequence":"additional","affiliation":[{"name":"Medicines Management and Pharmacy Service, Leeds Teaching Hospitals NHS Trust , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Wheatcroft","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus K.","family":"Witte*","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"key":"2026012114050288400_ehf212718-bib-0001","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1476-7120-4-20","article-title":"Incidence of post myocardial infarction left ventricular thrombus formation in the era of primary percutaneous intervention and glycoprotein IIb\/IIIa inhibitors. A prospective observational study","volume":"4","author":"Rehan","year":"2006","journal-title":"Cardiovasc Ultrasound"},{"key":"2026012114050288400_ehf212718-bib-0002","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.amjcard.2013.12.015","article-title":"Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention","volume":"113","author":"Gianstefani","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026012114050288400_ehf212718-bib-0003","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jcmg.2015.06.017","article-title":"Echocardiographic algorithm for post-myocardial infarction LV thrombus: a gatekeeper for thrombus evaluation by delayed enhancement CMR","volume":"9","author":"Weinsaft","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012114050288400_ehf212718-bib-0004","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12968-018-0494-3","article-title":"Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis","volume":"20","author":"Bulluck","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026012114050288400_ehf212718-bib-0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1753944717711139","article-title":"Challenges in management of left ventricular thrombus","volume":"11","author":"Habash","year":"2017","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2026012114050288400_ehf212718-bib-0006","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/01.CIR.75.5.1004","article-title":"Increased embolic risk in patients with left ventricular thrombi","volume":"75","author":"Stratton","year":"1987","journal-title":"Circulation"},{"key":"2026012114050288400_ehf212718-bib-0007","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/0735-1097(93)90409-T","article-title":"Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis","volume":"22","author":"Vaitkus","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"2026012114050288400_ehf212718-bib-0008","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114050288400_ehf212718-bib-0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11239-018-1656-8","article-title":"A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus","volume":"46","author":"Leow","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"2026012114050288400_ehf212718-bib-0010","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"2026012114050288400_ehf212718-bib-0011","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0735-1097(85)80336-3","article-title":"Embolic potential of left ventricular thrombus after myocardial infarction: a two-dimensional echocardiographic study of 119 patients","volume":"5","author":"Visser","year":"1985","journal-title":"J Am Coll Cardiol"},{"key":"2026012114050288400_ehf212718-bib-0012","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/0735-1097(90)90275-T","article-title":"Natural history of left ventricular thrombi: their appearance and resolution in the posthospitalization period of acute myocardial infarction","volume":"15","author":"Keren","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"2026012114050288400_ehf212718-bib-0013","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-104-5-689","article-title":"Intracardiac thrombi and systemic embolization","volume":"104","author":"Meltzer","year":"1986","journal-title":"Ann Intern Med"},{"key":"2026012114050288400_ehf212718-bib-0014","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7326\/0003-4819-100-6-789","article-title":"Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography","volume":"100","author":"Weinreich","year":"1984","journal-title":"Ann Intern Med"},{"key":"2026012114050288400_ehf212718-bib-0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012114050288400_ehf212718-bib-0016","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012114050288400_ehf212718-bib-0017","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012114050288400_ehf212718-bib-0018","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012114050288400_ehf212718-bib-0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181000","article-title":"Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: a retrospective register study","volume":"12","author":"Sjogren","year":"2017","journal-title":"PLoS ONE"},{"key":"2026012114050288400_ehf212718-bib-0020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ahj.2016.05.007","article-title":"Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF)","volume":"178","author":"Lip","year":"2016","journal-title":"Am Heart J"},{"key":"2026012114050288400_ehf212718-bib-0021","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.amjcard.2018.09.026","article-title":"Efficacy of direct acting oral anticoagulant drugs in treatment of left atrial appendage thrombus in patients with atrial fibrillation","volume":"123","author":"Fleddermann","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026012114050288400_ehf212718-bib-0022","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/eb-2012-100877","article-title":"Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes","volume":"18","author":"Witte","year":"2013","journal-title":"Evid Based Med"},{"key":"2026012114050288400_ehf212718-bib-0023","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","article-title":"Warfarin and aspirin in patients with heart failure and sinus rhythm","volume":"366","author":"Homma","year":"2012","journal-title":"N Engl J Med"},{"key":"2026012114050288400_ehf212718-bib-0024","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/CIRCULATIONAHA.108.801753","article-title":"Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the warfarin and antiplatelet therapy in chronic heart failure (WATCH) trial","volume":"119","author":"Massie","year":"2009","journal-title":"Circulation"},{"key":"2026012114050288400_ehf212718-bib-0025","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"2026012114050288400_ehf212718-bib-0026","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease","volume":"379","author":"Zannad","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114050288400_ehf212718-bib-0027","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012114050288400_ehf212718-bib-0028","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026012114050288400_ehf212718-bib-0029","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114050288400_ehf212718-bib-0030","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012114050288400_ehf212718-bib-0031","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"2026012114050288400_ehf212718-bib-0032","first-page":"A25","article-title":"36 Triple therapy anticoagulation following percutaenous coronary intervention (PCI) with novel oral anticoagulants (NOAC) is safe and has no adverse effects on bleeding post procedure when compared to triple therapy with vitamin K antagonist (VKA)","volume":"102","author":"Amin","year":"2016","journal-title":"Heart"},{"key":"2026012114050288400_ehf212718-bib-0033","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.jacc.2018.07.054","article-title":"Combining oral anticoagulants with platelet inhibitors in patients with atrial fibrillation and coronary disease","volume":"72","author":"Sindet-Pedersen","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114050288400_ehf212718-bib-0034","first-page":"S143","article-title":"Treatment of left ventricular thrombus using warfarin versus direct oral anticoagulants following anterior myocardial infarction","volume":"34","author":"Jaidka","year":"2018","journal-title":"Can J Cardiol"},{"key":"2026012114050288400_ehf212718-bib-0035","doi-asserted-by":"crossref","first-page":"A981","DOI":"10.1016\/S0735-1097(18)31522-5","article-title":"Direct oral anticoagulants compared to warfarin for left ventricular thrombi: a single center experience","volume":"71","author":"Robinson","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114050288400_ehf212718-bib-0036","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MBC.0000000000000801","article-title":"Efficacy of direct oral anticoagulants on left ventricular thrombus","volume":"30","author":"Turgay Yildirim","year":"2019","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2026012114050288400_ehf212718-bib-0037","first-page":"1","article-title":"Use of direct oral anticoagulants in the treatment of left ventricular thrombus: systematic review of current literature","author":"Kajy","year":"2019","journal-title":"Am J Ther"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12718","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12718","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12718","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/5\/2032\/65806885\/eschf_7_5_2032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/5\/2032\/65806885\/eschf_7_5_2032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:05:30Z","timestamp":1769022330000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/5\/2032\/8372023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,6,25]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12718","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,6,25]]},"assertion":[{"value":"2019-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}